JP2009137992A5 - - Google Patents

Download PDF

Info

Publication number
JP2009137992A5
JP2009137992A5 JP2009004309A JP2009004309A JP2009137992A5 JP 2009137992 A5 JP2009137992 A5 JP 2009137992A5 JP 2009004309 A JP2009004309 A JP 2009004309A JP 2009004309 A JP2009004309 A JP 2009004309A JP 2009137992 A5 JP2009137992 A5 JP 2009137992A5
Authority
JP
Japan
Prior art keywords
peptide
column
concentration
peptides
toxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009004309A
Other languages
English (en)
Other versions
JP4484941B2 (ja
JP2009137992A (ja
Filing date
Publication date
Priority claimed from US09/820,053 external-priority patent/US6875744B2/en
Application filed filed Critical
Publication of JP2009137992A publication Critical patent/JP2009137992A/ja
Publication of JP2009137992A5 publication Critical patent/JP2009137992A5/ja
Application granted granted Critical
Publication of JP4484941B2 publication Critical patent/JP4484941B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

刺激及び増殖のために望ましいペプチドを選択することもできる。次の表２９は、望ましいペプチドの例を掲げており、「Ｘ」印は、そのペプチドが、前記表の項目欄に記載した特性に対する望ましいペプチドであることを表している。ペプチドは０.１μｇ/ｍｌ〜１.０μｇ/ｍｌの濃度で白血球を刺激するペプチドが好ましい。この濃度では、前記ペプチドは、赤血球、ＷＩ−３８線維芽細胞又はヒトの白血球に対して非毒性だからである。ペプチドは０.１μｇ/ｍｌ〜１.０μｇ/ｍｌで線維芽細胞を刺激するペプチドが好ましい。この濃度では、前記ペプチドは非毒性だからである。
表２９の中に、P146(SEQ108)(長さ＝13)及びP97(SEQ165)(長さ＝13)を追加する。これらのペプチドは、両方とも、白血球の欄及び線維芽細胞の欄に「Ｘ」印が付されるものとする。
JP2009004309A 2001-03-28 2009-01-13 生物活性を有する短ペプチド及び該ペプチドの使用方法 Expired - Lifetime JP4484941B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27950501P 2001-03-28 2001-03-28
US09/820,053 US6875744B2 (en) 2001-03-28 2001-03-28 Short bioactive peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002578411A Division JP4310107B2 (ja) 2001-03-28 2002-03-28 生物活性を有する短ペプチド及び該ペプチドの使用方法

Publications (3)

Publication Number Publication Date
JP2009137992A JP2009137992A (ja) 2009-06-25
JP2009137992A5 true JP2009137992A5 (ja) 2010-04-02
JP4484941B2 JP4484941B2 (ja) 2010-06-16

Family

ID=26959709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002578411A Expired - Lifetime JP4310107B2 (ja) 2001-03-28 2002-03-28 生物活性を有する短ペプチド及び該ペプチドの使用方法
JP2009004309A Expired - Lifetime JP4484941B2 (ja) 2001-03-28 2009-01-13 生物活性を有する短ペプチド及び該ペプチドの使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002578411A Expired - Lifetime JP4310107B2 (ja) 2001-03-28 2002-03-28 生物活性を有する短ペプチド及び該ペプチドの使用方法

Country Status (9)

Country Link
US (1) US7381704B2 (ja)
EP (2) EP1379265A4 (ja)
JP (2) JP4310107B2 (ja)
KR (1) KR100891157B1 (ja)
AU (1) AU2002255952A1 (ja)
CA (1) CA2441562C (ja)
ES (1) ES2389285T3 (ja)
HK (1) HK1135330A1 (ja)
WO (1) WO2002079408A2 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004229465B2 (en) * 2003-04-09 2010-04-29 The United States Of America Department Of Veterans Affairs Compositions and methods related to production of erythropoietin
JP2005281225A (ja) * 2004-03-30 2005-10-13 Japan Science & Technology Agency 新規塩基性抗菌ペプチド及びその利用
WO2007014391A2 (en) * 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
US7601361B2 (en) * 2005-10-03 2009-10-13 E. I. Du Pont De Nemours And Company Process for providing antimicrobial surfaces
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN105288581A (zh) * 2006-06-01 2016-02-03 治疗剂肽有限公司 聚合生物表面活性剂
BRPI0713153B8 (pt) 2006-06-13 2021-05-25 Helix Biomedix Inc tetrapeptídeo capaz de induzir a produção das proteínas da matriz extracelular e composição o compreendendo
KR100742982B1 (ko) * 2006-06-22 2007-07-26 케이맥(주) 초점 타원계측기
ES2404669T3 (es) * 2007-01-05 2013-05-28 Helix Biomedix, Inc. Péptidos bioactivos cortos para modulación celular e inmunológica
CN101848927B (zh) * 2007-05-01 2014-10-22 圣保罗州支援研究基金会 镇痛化合物
CN101855235B (zh) 2007-10-29 2013-04-24 赫里克斯生物医疗公司 保护性皮肤护理四肽
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP2168591A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
ITBS20120126A1 (it) * 2012-08-01 2014-02-02 Paoli Ambrosi Gianfranco De Composizione antibatterica per uso topico
CN105283198A (zh) * 2013-04-09 2016-01-27 卡勒德·莫希·埃尔丹·伊罗丹 作为恶性肿瘤控制中的单一疗法的新型肽
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
JP6613312B2 (ja) * 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
CN105061562B (zh) * 2015-09-16 2018-01-12 山东电力中心医院 一种具有抗肺癌作用的寡肽及其应用
US9439917B1 (en) 2015-12-28 2016-09-13 Shetal Amit Shah Anti-blepharitis compositions and their use
WO2017151617A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
WO2019210377A1 (en) * 2018-04-30 2019-11-07 L'oreal Bioactive peptides having high binding affinity to human muscular nicotinic acetylcholine receptor
FR3099060B1 (fr) * 2019-07-26 2022-01-14 Bionuclei Complexe hybride mineral et organique et son utilisation pour le maintien de l’equilibre microbiologique de la peau et/ou d’une composition cosmetique et/ou dermopharmaceutique

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355104A (en) 1980-06-17 1982-10-19 Kabigen Ab Bacteriolytic proteins
US4520016A (en) 1980-06-17 1985-05-28 Kabigen Ab Bacteriolytic proteins
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
CA1327311C (en) 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
WO1989000194A1 (en) 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
AU5433190A (en) * 1989-04-10 1990-11-16 Louisiana State University And Agricultural And Mechanical College Lytic peptides, use for growth, infection and cancer
AU654714B2 (en) * 1991-04-08 1994-11-17 Magainin Pharmaceuticals, Inc. Novel peptide compositions and uses therefor
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
WO1994028921A1 (en) 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US5789542A (en) 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
IL114697A0 (en) * 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US6566334B1 (en) 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CA2396422A1 (en) 2000-01-06 2001-07-12 Monsanto Technology Llc Preparation of deallergenized proteins and permuteins

Similar Documents

Publication Publication Date Title
JP2009137992A5 (ja)
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
DE602006012469D1 (de) Bipolare medizinische elektrodenanordnung mit kanüle und entfernbarer anschlusselektrode
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
MY148723A (en) Use of pinolenic acid for the treatment of obesity
BRPI0814737A2 (pt) Composição, métodos para reduzir, retardar ou de um outro modo inibir o crescimento e/ou replicação de hcv, para prevenir a infecção de uma célula exposta a hcv, para tratar terapeuticamente ou profilaticamente um paciente exposto ou infectado com hcv, e para tratar hepatite c, e, uso de uma composição.
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
UA95715C2 (ru) Фосфадиазиновые производные, фармацевтическая композиция и их применение
NO20065536L (no) Behandling av astma hos barn
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2008045564A8 (en) Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
MX2010001849A (es) Depsipeptidos ciclicos.
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
RU2007122391A (ru) S-миртазапин для лечения приливов
ITMI20050887A1 (it) Letto perfezionato elevabile e regolabile in modo da facilitare la salita e la discesa del paziente
HK1106253A1 (en) Desoxo-nonadepsipeptides
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases